117 related articles for article (PubMed ID: 8309439)
21. Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma.
Dauer LT; St Germain J; Williamson MJ; Zanzonico P; Modak S; Cheung NK; Divgi C
Health Phys; 2007 Jan; 92(1):33-9. PubMed ID: 17164597
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer.
Divgi CR; O'Donoghue JA; Welt S; O'Neel J; Finn R; Motzer RJ; Jungbluth A; Hoffman E; Ritter G; Larson SM; Old LJ
J Nucl Med; 2004 Aug; 45(8):1412-21. PubMed ID: 15299069
[TBL] [Abstract][Full Text] [Related]
23. Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer.
van Zanten-Przybysz I; Molthoff CF; Roos JC; Plaizier MA; Visser GW; Pijpers R; Kenemans P; Verheijen RH
J Nucl Med; 2000 Jul; 41(7):1168-76. PubMed ID: 10914906
[TBL] [Abstract][Full Text] [Related]
24. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
[TBL] [Abstract][Full Text] [Related]
25. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody.
Matthews DC; Badger CC; Fisher DR; Hui TE; Nourigat C; Appelbaum FR; Martin PJ; Bernstein ID
Cancer Res; 1992 Mar; 52(5):1228-34. PubMed ID: 1531324
[TBL] [Abstract][Full Text] [Related]
26. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
[TBL] [Abstract][Full Text] [Related]
27. Double-tracer dosimetry of organs in assessment of bone marrow involvement by two monoclonal antibodies.
Korppi-Tommola ET; Kairemo KJ; Jekunen AP; Niskanen EO; Savolainen SE
Acta Oncol; 1996; 35(3):357-65. PubMed ID: 8679267
[TBL] [Abstract][Full Text] [Related]
28. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
Zhu H; Jain RK; Baxter LT
J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
[TBL] [Abstract][Full Text] [Related]
29. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
30. Single-cell dosimetry for radioimmunotherapy of B-cell lymphoma patients with special reference to leukemic spread.
Hindorf C; Emfietzoglou D; Lindén O; Bousis C; Fotopoulos A; Kostarelos K; Flux GD
Cancer Biother Radiopharm; 2007 Jun; 22(3):357-66. PubMed ID: 17651041
[TBL] [Abstract][Full Text] [Related]
31. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy.
Emfietzoglou D; Kostarelos K; Sgouros G
J Nucl Med; 2001 Mar; 42(3):499-504. PubMed ID: 11337529
[TBL] [Abstract][Full Text] [Related]
32. Impact of scatter and attenuation corrections for iodine-131 two-dimensional quantitative imaging in patients.
Delpon G; Ferrer L; Lisbona A; Bardiès M
Cancer Biother Radiopharm; 2003 Apr; 18(2):191-9. PubMed ID: 12804044
[TBL] [Abstract][Full Text] [Related]
33. 3D calculation of absorbed dose for 131I-targeted radiotherapy: a Monte Carlo study.
Saeedzadeh E; Sarkar S; Abbaspour Tehrani-Fard A; Ay MR; Khosravi HR; Loudos G
Radiat Prot Dosimetry; 2012 Jul; 150(3):298-305. PubMed ID: 22069233
[TBL] [Abstract][Full Text] [Related]
34. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
[TBL] [Abstract][Full Text] [Related]
35. MABDOSE. II: Validation of a general purpose dose estimation code.
Johnson TK; McClure D; McCourt S
Med Phys; 1999 Jul; 26(7):1396-403. PubMed ID: 10435544
[TBL] [Abstract][Full Text] [Related]
36. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
[TBL] [Abstract][Full Text] [Related]
37. Biodistribution and tumour localisation of 131I SWA11 recognising the cluster w4 antigen in patients with small cell lung cancer.
Ledermann JA; Marston NJ; Stahel RA; Waibel R; Buscombe JR; Ell PJ
Br J Cancer; 1993 Jul; 68(1):119-21. PubMed ID: 8391302
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
[TBL] [Abstract][Full Text] [Related]
39. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software.
Kolbert KS; Pentlow KS; Pearson JR; Sheikh A; Finn RD; Humm JL; Larson SM
J Nucl Med; 2007 Jan; 48(1):143-9. PubMed ID: 17204711
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.
Sharkey RM; Juweid M; Shevitz J; Behr T; Dunn R; Swayne LC; Wong GY; Blumenthal RD; Griffiths GL; Siegel JA
Cancer Res; 1995 Dec; 55(23 Suppl):5935s-5945s. PubMed ID: 7493374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
